Clinical Trial Detail

NCT ID NCT02831491
Title A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company

lung non-small cell carcinoma


Docetaxel + Ramucirumab

Age Groups: adult senior

No variant requirements are available.